Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomized, double-blind phase 3 trial - Eggermont, A M; Chiarion-Sileni, V; Grob, J J (Lancet Oncol, 2015)
et al.